MedTrace Logo

Validation of TERA Bio Station T101 of COVID-19 Tested Population.

NCT05088902 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2021-12-21

No results posted yet for this study

Summary

TERABio Ltd. has developed a rapid screening tool intended to determine if a tested individual is COVID-19-free (Negative to COVID-19).

Conditions

Interventions

DIAGNOSTIC_TEST

TERABio Ltd.

Covid- 19 investigational breath test compared to RT- PCR test. TERABio Ltd. has developed a rapid screening tool intended to determine if a tested individual is COVID-19-free (Negative to COVID-19 ).

Sponsors & Collaborators

  • Tera Group

    lead INDUSTRY

Principal Investigators

  • Nihat Müjdat Hökenek, MD · TR Ministry of Health Istanbul Provincial Health Directorate Kartal Dr. Lütfi Kirdar City Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-22
Primary Completion
2022-03-06
Completion
2022-06-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05088902 on ClinicalTrials.gov